<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff= 20 231106111053&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed -2<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231106111053&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 6 日星期一 16:10:56 +0000</lastbuilddate><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>儿科心肺复苏期间呼气末二氧化碳、心肺复苏质量和生存之间的关联</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>背景：在成人心肺骤停的实验室和临床研究的支持下，复苏指南建议监测呼气末二氧化碳（ETCO2）作为心肺复苏质量的指标，但指出“尚未建立指导儿童治疗的具体值”。方法：这项前瞻性观察队列研究是 NHLBI 资助的一项针对 ICU-RESUSitation 试验中儿童的辅助研究 (NCT02837497)。住院儿童（≤18 岁且≥37 周... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 6 日。doi：10.1161/CIRCULATIONAHA.123.066659。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>在成人心肺骤停的实验室和临床研究的支持下，复苏指南建议监测呼气末二氧化碳（ETCO2）作为心肺复苏质量的指标，但指出“尚未建立指导儿童治疗的具体值”。<b>方法：</b>这项前瞻性观察队列研究是一项 NHLBI 资助的针对<i>ICU-RESUS</i>引文试验 (NCT02837497) 儿童的辅助研究。接受过任何胸外按压的住院儿童（≤18 岁且孕后≥37 周）包括心肺骤停持续时间、在 CPR 开始时有气管插管或气管切开插管、以及可评估的逮捕期间 ETCO2 数据。主要暴露是 CPR 前 10 分钟内事件水平的平均 ETCO2（分为 ≥20 mmHg）与基于成人文献的 &lt;20 mmHg 相比）。主要结局是出院时的生存率。次要结局是自主循环 (ROSC) 的持续恢复、神经系统结果良好的出院时的生存率以及幸存者中的新发病率。泊松回归关联测量ETCO2 与结果之间的关系以及 ETCO2 与其他 CPR 特征之间的关联：1) 有创测量的收缩压和舒张压，2) CPR 质量和胸外按压力学指标（即 CPR 开始时间、胸外按压频率、深度和<b>结果：</b>在纳入的 234 名患者中，133 名 (57%) 的事件水平平均 ETCO2 ≥20 mmHg。在控制<i>先验</i>协变量后，平均 ETCO2 ≥20 mmHg 与较高的出院生存率相关（86/ 133 (65%) 对比 48/101 (48%)；aRR 1.33，CI95 1.04 - 1.69，p=0.023) 和 ROSC (95/133 (71%) 59/101 (58%)；aRR 1.22，CI95 1.00 - 1.49，p=0.046）与较低值相比。ETCO2 ≥20 mmHg 与生存者的良好神经系统结果或新发病率无关。平均 ETCO2 ≥20 mmHg 与 CPR 期间较高的收缩压和舒张压、较低的 CPR 通气量相关与较低值相比，CPR 前逮捕持续时间较短。ETCO2 组之间的胸外按压率、深度和分数没有差异。<b>结论：</b>在这项针对院内心肺骤停儿童的多中心研究中，ETCO2 ≥20 mmHg 与具有更好的结果和更高的逮捕内血压，但胸外按压质量指标却没有。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37929615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37929615</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066659>10.1161/CIRCULATIONAHA.123.066659</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37929615</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>瑞安·W·摩根</dc:creator><dc:creator>罗恩·W·里德</dc:creator><dc:creator>迪特·本德</dc:creator><dc:creator>凯利玛丽·K·库珀</dc:creator><dc:creator>斯图尔特·H·弗里斯</dc:creator><dc:creator>凯瑟琳·格雷厄姆</dc:creator><dc:creator>凯瑟琳·L·梅尔特</dc:creator><dc:creator>彼得·莫拉尼</dc:creator><dc:creator>罗伯特·默里</dc:creator><dc:creator>维奈·M·纳德卡尼</dc:creator><dc:creator>C纳塔拉吉</dc:creator><dc:creator>切拉·帕尔默</dc:creator><dc:creator>尼拉杰·斯里瓦斯塔瓦</dc:creator><dc:creator>布拉德利·蒂尔福德</dc:creator><dc:creator>希瑟·沃尔夫</dc:creator><dc:creator>安德鲁·耶茨</dc:creator><dc:creator>罗伯特·伯格</dc:creator><dc:creator>罗伯特·萨顿</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>儿科心肺复苏期间呼气末二氧化碳、心肺复苏质量和生存之间的关联</dc:title><dc:identifier>下午:37929615</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066659</dc:identifier></item><item><title>炎症和胆固醇作为 13970 名当代他汀类药物不耐受高危患者心血管事件的预测因子</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>背景：在接受他汀类药物治疗达到指南推荐胆固醇水平的患者中，通过高敏 C 反应蛋白 (hsCRP) 评估的残余炎症风险至少与通过低密度评估的残余风险一样有力地预测未来心血管事件脂蛋白胆固醇 (LDLC)。这些关系是否存在于具有较高 LDLC 水平的他汀类药物不耐受患者中尚不确定，但对预防性治疗的选择具有影响，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 6 日。doi：10.1161/CIRCULATIONAHA.123.066213。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>在接受他汀类药物治疗达到指南推荐胆固醇水平的患者中，通过高敏 C 反应蛋白 (hsCRP) 评估的残余炎症风险至少与通过低密度评估的残余风险一样有力地预测未来心血管事件脂蛋白胆固醇 (LDLC)。这些关系是否存在于他汀类药物不耐受且 LDLC 水平较高的患者中是否存在尚不确定，但对预防性治疗的选择具有影响，包括 Bempedoic Acid，一种降低 LDLC 和 hsCRP 的药物。<b>方法：</b>跨国公司 CLEAR -结果试验（通过 Bempedoic Acid 降低胆固醇，ACL 抑制方案结果试验）将 13970 名他汀类药物不耐受患者随机分配至每天 180 毫克口服 bempedoic Acid 或匹配的安慰剂组，并对他们进行心肌梗死事件的 4 成分复合治疗，中风、冠状动脉血运重建或心血管死亡以及全因死亡率。在调整传统危险因素和随机治疗分配后，将基线 hsCRP 和 LDLC 增加的四分位数评估为未来不良事件的预测因子。<b>结果：</b>与安慰剂相比，bempedoic Acid 6 个月时，中位 hsCRP 降低 21.6%，平均 LDLC 水平降低 21.1%。基线 hsCRP 与主要心血管事件的主要复合终点显着相关（最高与最低 hsCRP 四分位数；风险比 [HR]，1.43 [95% CI ，1.24-1.65]）、心血管死亡率（HR，2.00 [95% CI，1.53-2.61]）和全因死亡率（HR，2.21 [95% CI，1.79-2.73]）。基线 LDLC 四分位（最高与主要复合心血管终点（HR，1.19 [95% CI，1.04-1.37]）与未来事件的相关性较小（HR，1.19 [95% CI，1.04-1.37]），心血管死亡率为中性（HR，0.90 [95% CI，0.70-1.17]），全因死亡率（HR，0.95 [95% CI，0.78-1.16]）。无论 LDLC 水平如何，hsCRP 升高的患者的风险都很高。Bempedoic 酸在减少所有 hsCRP 和 LDLC 水平的心血管事件方面表现出相似的功效。<b>结论：</b>在当代他汀类药物不耐受的患者中，通过 hsCRP 评估的炎症比通过 LDLC 评估的高脂血症更能预测未来心血管事件和死亡的风险。与安慰剂相比，bempedoic 酸在降低 hsCRP 和 LDLC 层的心血管风险方面具有相似的功效。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37929602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37929602</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066213>10.1161/CIRCULATIONAHA.123.066213</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37929602</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>保罗·M·里德克</dc:creator><dc:creator>雷雷</dc:creator><dc:creator>迈克尔·J·路易</dc:creator><dc:creator>塔里克·哈达德</dc:creator><dc:creator>斯蒂芬·尼科尔斯</dc:creator><dc:creator>迈克尔·林科夫</dc:creator><dc:creator>彼得·利比</dc:creator><dc:creator>史蒂文·E·尼森</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>炎症和胆固醇作为 13970 名当代他汀类药物不耐受高危患者心血管事件的预测因子</dc:title><dc:identifier>下午:37929602</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066213</dc:identifier></item><item><title>诊断模仿：生物瓣膜培养阴性感染性心内膜炎，表现为 ANCA 血管炎</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 6 日。doi：10.1161/CIRCULATIONAHA.123.067136。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37929592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37929592</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067136>10.1161 / CIRCULATIONAHA.123.067136</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37929592</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>大卫·E·汉密尔顿</dc:creator><dc:creator>桑德罗·K·辛蒂</dc:creator><dc:creator>凯瑟琳·J·拉佩迪斯</dc:creator><dc:creator>金·伊格尔</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>诊断模仿：生物瓣膜培养阴性感染性心内膜炎，表现为 ANCA 血管炎</dc:title><dc:identifier>下午:37929592</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067136</dc:identifier></item><item><title>遗传性肥厚型心肌病的外显率荟萃分析和疾病转变的系统评价</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>背景：肥厚型心肌病 (HCM) 的特点是不明原因的左心室肥大 (LVH)，通常是由编码肌节蛋白的基因中的致病性或可能致病性变异 (P/LP) 引起。并非所有亚临床变异携带者都会表现出临床明显的疾病，如外显率（罹患疾病的 G+ 比例）是可变的、与年龄相关且无法可靠预测。方法：对文献进行系统检索。我们采用随机... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 6 日。doi：10.1161/CIRCULATIONAHA.123.065987。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>肥厚型心肌病 (HCM) 的特点是不明原因的左心室肥大 (LVH)，通常是由编码肌节蛋白的基因中的致病性或可能致病性变异 (P/LP) 引起。并非所有亚临床变异携带者都会表现出临床明显的疾病，如外显率（罹患疾病的 G+ 比例）是可变的、与年龄相关且无法可靠预测。<b>方法：</b>对文献进行了系统检索。我们采用随机效应广义线性混合模型荟萃分析来对比横截面患病率两种不同背景下肌节基因的外显率和外显率：针对 HCM 患者和家庭的临床研究与基于人群/社区的研究。另外还分析了纵向家庭/临床研究，以调查随访期间从亚临床到明显 HCM 的表型转化率<b>结果：</b>评估了 455 份全文手稿。在家庭/临床研究中，诊断为 HCM 的患者中肌节变异的患病率为 34%。在级联过程中鉴定出携带 P/LP 变异的非先证者亲属中所有基因的外显率筛查率为 57%（95% 置信区间 [CI] [52,63]），HCM 诊断的平均年龄为 38 岁（95% CI [36, 40]）。肌球蛋白轻链的外显率约为 32%（肌<i>球蛋白</i>结合蛋白 C ( <i>MYBPC3</i> )、肌钙蛋白 T ( <i>TNNT2</i> ) 和肌钙蛋白 I ( <i>TNNI3</i> ) 约 60%，肌球蛋白重链 ( <i>MYH7</i> ) 约 65%。基于群体的遗传学研究表明，P /LP 肌节变异存在于背景人群中，但患病率较低，&lt;1%。偶然发现的 P/LP 变异携带者中 HCM 的外显率也显着降低；大约为 11%，动脉粥样硬化风险中的 0% 不等。英国生物银行的社区达到 18%。在纵向家族研究中，从平均年龄 16 岁开始，在平均约 8 年的随访中，所有基因的汇总表型转换为 15%。然而，短期基因-特定表型变化的转换范围为<i>MYBPC3</i>的 ~12% 到<i>MYH7</i>的 ~23%。<b>结论：</b> P/LP 变异的外显率变化很大，并受到当前未定义和上下文相关的遗传和环境因素的影响。需要进行额外的纵向研究提高对家庭和社区中真实终生外显率的了解，并确定从亚临床到明显 HCM 转变的驱动因素。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37929589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37929589</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065987>10.1161 / CIRCULATIONAHA.123.065987</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37929589</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>康斯坦丁·克里斯蒂安·托普莱斯亚努</dc:creator><dc:creator>亚历山大·C·佩雷拉</dc:creator><dc:creator>詹姆斯·C·穆恩</dc:creator><dc:creator>加布里埃拉·卡普尔</dc:creator><dc:creator>卡洛琳·Y·何</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>遗传性肥厚型心肌病的外显率荟萃分析和疾病转变的系统评价</dc:title><dc:identifier>下午:37929589</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065987</dc:identifier></item><item><title>骨髓细胞衍生的 IL1β 导致 HFpEF 患者出现肺动脉高压</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929582/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>结论：我们报告了一种用于研究 HFpEF 中 PH 和右心重塑的新模型，并且我们确定骨髓细胞来源的 IL-1β 是 HFpEF 中 PH 的重要贡献者。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 11 月 6 日。doi：10.1161/CIRCRESAHA.123.323119。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：射血分数保留的心力衰竭 (HFpEF) 中的肺动脉高压 (PH) 是一种常见且发病率很高的综合征，但对 PH-HFpEF 的驱动机制知之甚少。我们试图确定一种广为接受的 HFpEF 小鼠模型是否也表现出这种症状PH 的特征，我们试图找出可能驱动 HFpEF 肺血管系统早期重塑的途径。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：8周龄雄性和雌性C57BL/6J小鼠接受<sup>Nγ-</sup>硝基-L-精氨酸甲酯和高脂肪饮食或控制水和饮食2、5和12周。作为 HFpEF 的第二种模型进行了研究。通过批量和单细胞 RNA 测序鉴定了调节 PH 的早期途径。通过小鼠肺部的免疫染色或对 PH-HFpEF 患者进行临床尸检的肺切片证实了结果。使用 ELISA为了验证右心导管插入术时获得的小鼠肺、小鼠血浆以及 PH-HFpEF 患者血浆中的 IL-1β（白介素-1β）。使用氯膦酸盐脂质体和抗 IL-1β 抗体分别消耗巨噬细胞和 IL-1β，以评估它们对小鼠模型中 HFpEF 肺血管重塑的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果： <sup>Nγ-硝基</sup>-L-精氨酸甲酯/高脂饮食治疗的小鼠出现肺PH、小血管肌肉化和右心功能障碍。在全肺的批量RNA测序分析中，炎症相关基因本体被过度表达，小鼠和人 PH-HFpEF 肺中 CD68 <sup>+</sup>细胞增加。细胞因子分析显示小鼠和人血浆中 IL-1β 增加。最后，氯膦酸盐脂质体治疗小鼠可预防 N <sup>γ</sup> -硝基-L-精氨酸甲酯中的 PH /高脂肪饮食治疗的小鼠，IL-1β消耗也减弱了N <sup>γ</sup> -硝基-L-精氨酸甲酯/高脂肪饮食治疗的小鼠的PH。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们报告了一种用于研究 HFpEF 中 PH 和右心重塑的新模型，并且我们确定骨髓细胞来源的 IL-1β 是 HFpEF 中 PH 的重要贡献者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37929582/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37929582</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323119>10.1161/CIRCRESAHA.123.323119</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37929582</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>维内特·阿格拉瓦尔</dc:creator><dc:creator>乔纳森·克罗普斯基</dc:creator><dc:creator>贾森·戈基</dc:creator><dc:creator>伊丽莎白·科贝克</dc:creator><dc:creator>马修·B·墨菲</dc:creator><dc:creator>凯瑟琳·穆雷</dc:creator><dc:creator>尼基·L·福琼</dc:creator><dc:creator>克里斯蒂·摩尔</dc:creator><dc:creator>大卫·F·梅奥利</dc:creator><dc:creator>肯·莫纳汉</dc:creator><dc:creator>颜如素</dc:creator><dc:creator>托马斯·布莱克威尔</dc:creator><dc:creator>迪帕克·K·古普塔</dc:creator><dc:creator>梅加·H·塔拉蒂</dc:creator><dc:creator>桑蒂·格拉德森</dc:creator><dc:creator>艾丽卡·J·卡里尔</dc:creator><dc:creator>詹姆斯·D·韦斯特</dc:creator><dc:creator>安娜·R·汉内斯</dc:creator><dc:date>2023-11-06</dc:date><dc:source>流通研究</dc:source><dc:title>骨髓细胞衍生的 IL1β 导致 HFpEF 患者出现肺动脉高压</dc:title><dc:identifier>下午：37929582</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323119</dc:identifier></item><item><title>两种疾病的故事：孟德尔原理的相互作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 6 日。doi：10.1161/CIRCULATIONAHA.123.067135。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37929575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37929575</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067135>10.1161/CIRCULATIONAHA.123.067135</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37929575</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>雷纳尔多·H·桑切斯</dc:creator><dc:creator>维娜·拉贾拉姆</dc:creator><dc:creator>尼古拉斯·亨德伦</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>两种疾病的故事：孟德尔原理的相互作用</dc:title><dc:identifier>下午:37929575</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067135</dc:identifier></item><item><title>冠状动脉疾病患者的非缺血性或双重心肌病</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>背景：阻塞性冠状动脉疾病 (CAD) 的随机试验在很大程度上表明冠状动脉血运重建对预后没有益处。虽然有几个潜在原因导致缺乏益处，但一个尚未充分探索的可能原因是同时存在非缺血性心肌病 (NICM)我们调查了 CAD 患者 (CAD-NICM) 中 NICM 的患病率和预后意义。方法：我们对连续患有阻塞性 CAD 的患者进行了登记研究... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 6 日。doi：10.1161/CIRCULATIONAHA.123.067032。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>阻塞性冠状动脉疾病 (CAD) 的随机试验在很大程度上表明冠状动脉血运重建对预后没有益处。虽然有几个潜在原因导致缺乏益处，但一个尚未充分探索的可能原因是同时存在非缺血性心肌病 (NICM)我们调查了 CAD 患者中 NICM 的患病率和预后意义（CAD-NICM）。<b>方法：</b>我们对连续接受冠状动脉造影的阻塞性 CAD 患者进行了登记研究，这些患者接受了对比增强心血管磁共振成像 (CMR) 进行评估从 2004 年到 2020 年，我们对 4 家医院的心室功能和疤痕进行了评估。我们使用 CMR 和冠状动脉造影数据确定了心肌病的存在和原因，对临床结果不知情。主要结果是全因死亡或心力衰竭 (HF) 的复合结果<b>结果：</b> 3,023 名患者（中位年龄 66 岁，76% 为男性）中，18.2% 没有心肌病 (CAD+noCM)，64.8% 患有缺血性心肌病。 (CAD+ICM)，9.3% 患有 CAD+NICM，7.7% 患有双重心肌病 (CAD+dualCM)，定义为 ICM 和 NICM。因此，16.9% 患有 CAD+NICM 或 DualCM。中位随访时间为 4.8年（四分位距，2.9，7.6），1,116 名患者经历了主要结局。在 Cox 多变量分析中，与 CAD+ICM 相比，CAD+NICM 或 DualCM 与主要结局的较高风险独立相关 [调整后的风险比 (HR ) 1.23；95% 置信区间 (CI) 1.06-1.43；P = 0.007] 调整潜在混杂因素后。CAD+NICM 或双CM 的次要结局全因死亡和心力衰竭住院的风险也较高（HR 1.21；1.23；95% 置信区间 (CI) 1.06-1.43；P = 0.007）。 95% CI 1.02-1.43；P = 0.032；HR 1.37；95% CI 1.11-1.69；P = 0.003），而心血管死亡风险与 CAD+ICM 没有差异（HR 1.15；95% CI 0.89） -1.48；P = 0.28）。<b>结论：</b>在转诊进行临床 CMR 的 CAD 患者中，每 6 名患者中就有 1 名发现 NICM 或双重CM，并且与 ICM 相比，与更差的长期结果相关。在阻塞性 CAD 患者中，巧合NICM 或双重CM 可能导致冠状动脉血运重建缺乏预后益处。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37929565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37929565</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067032>10.1161 / CIRCULATIONAHA.123.067032</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37929565</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>帕拉格·巴瓦斯卡</dc:creator><dc:creator>尼古拉斯·托马斯</dc:creator><dc:creator>哈立德·F·伊斯梅尔</dc:creator><dc:creator>郭育根</dc:creator><dc:creator>三亚奇卡拉</dc:creator><dc:creator>帕尔·萨蒂亚吉特·辛格·阿特瓦尔</dc:creator><dc:creator>艾莉森·拉纳姆</dc:creator><dc:creator>阿查·贾达夫</dc:creator><dc:creator>阿贝尔·胡克·门德斯</dc:creator><dc:creator>伊尚·纳德卡尼</dc:creator><dc:creator>多米尼克·罗杰·弗里里希斯</dc:creator><dc:creator>普拉蒂克·斯里尼瓦斯·韦兰吉</dc:creator><dc:creator>埃尔甘多</dc:creator><dc:creator>哈桑·阿克拉姆</dc:creator><dc:creator>阿迪南坎达</dc:creator><dc:creator>切坦·谢诺伊</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>冠状动脉疾病患者的非缺血性或双重心肌病</dc:title><dc:identifier>下午:37929565</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067032</dc:identifier></item><item><title> TAVI 后的长期结果和设备故障</title><link/>https://pubmed.ncbi.nlm.nih.gov/37923830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 11 月 3 日。doi：10.1038/s41569-023-00954-3。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37923830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37923830</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00954-3>10.1038/s41569-023-00954-3</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37923830</guid><pubDate> Sat, 04 Nov 2023 06:00:00 -0400</pubDate><dc:creator>马可·巴尔班蒂</dc:creator><dc:creator>约翰·G·韦伯</dc:creator><dc:date>2023-11-04</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>TAVI 后的长期结果和设备故障</dc:title><dc:identifier>下午:37923830</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00954-3</dc:identifier></item><item><title> NLRP3炎症小体和细胞焦亡在心血管疾病中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37923829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>心肌缺血性和非缺血性损伤时会发生强烈的、刻板的炎症反应。含有 NACHT、LRR 和 PYD 结构域的蛋白 3 (NLRP3) 炎性体是一种精细调节的大分子蛋白复合物，可感知损伤并触发和放大通过激活 caspase 1 引起炎症反应；将促炎细胞因子（例如 IL-1β 前体和 IL-18 前体）裂解为其成熟形式；以及诱导炎症细胞死亡…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 11 月 3 日。doi：10.1038/s41569-023-00946-3。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心肌缺血性和非缺血性损伤时会发生强烈的、刻板的炎症反应。含有 NACHT、LRR 和 PYD 结构域的蛋白 3 (NLRP3) 炎性体是一种精细调节的大分子蛋白复合物，可感知损伤并触发和放大通过激活 caspase 1 引起炎症反应；将促炎细胞因子（例如 IL-1β 前体和 IL-18 前体）裂解为其成熟形式；以及诱导炎症细胞死亡（细胞焦亡）。 IL-1β 和 IL-18 活性的阻断剂已被证明可以减少对心肌和心包的损伤，有利于炎症的消退并保护心脏功能。在这篇综述中，我们讨论了 NLRP3 炎症小体的成分及其形成方式并在各种缺血性和非缺血性心脏病（急性心肌梗塞、心功能不全和重构、动脉粥样硬化血栓形成、心肌炎和心包炎、心脏毒性和心脏结节病）中被激活。我们还总结了针对 NLRP3 炎性体的药物研究的当前临床前和临床证据及相关细胞因子。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37923829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37923829</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00946-3>10.1038/s41569-023-00946-3</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37923829</guid><pubDate> Sat, 04 Nov 2023 06:00:00 -0400</pubDate><dc:creator>斯特凡诺·托尔多</dc:creator><dc:creator>安东尼奥·阿巴特</dc:creator><dc:date>2023-11-04</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>NLRP3炎症小体和细胞焦亡在心血管疾病中的作用</dc:title><dc:identifier>下午:37923829</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00946-3</dc:identifier></item><item><title> SWI/SNF 目标的全球识别揭示了 EP400 的补偿</title><link/>https://pubmed.ncbi.nlm.nih.gov/37922899/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>哺乳动物 SWI/SNF 染色质重塑复合物移动并驱逐基因启动子和增强子处的核小体，以调节 DNA 访问。尽管 SWI/SNF 亚基在疾病中通常发生突变，但由于我们无法预测 SWI/SNF 基因靶点以及相互矛盾的研究，治疗选择受到限制功能意义。在这里，我们利用 SWI/SNF 重塑的快速作用抑制剂来阐明 SWI/SNF 的直接目标和作用。阻断 SWI/SNF 活性会导致... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 29 日：S0092-8674(23)01088-7. doi: 10.1016/j.cell.2023.10.006. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">哺乳动物 SWI/SNF 染色质重塑复合物移动并驱逐基因启动子和增强子处的核小体，以调节 DNA 访问。尽管 SWI/SNF 亚基在疾病中通常发生突变，但由于我们无法预测 SWI/SNF 基因靶点以及相互矛盾的研究，治疗选择受到限制功能意义。在这里，我们利用 SWI/SNF 重塑的快速作用抑制剂来阐明 SWI/SNF 的直接目标和作用。阻断 SWI/SNF 活性会导致染色质可及性和转录的快速和全面丧失。增强子，我们发现了一个EP400/TIP60 重塑剂的补偿作用，在 SWI/SNF 长期丢失期间重新建立大多数启动子的可及性。事实上，我们在癌细胞系和人类癌症患者数据中观察到 EP400 和 SWI/SNF 之间的合成致死性。我们的数据定义了一组分子基因组特征可准确预测不同癌细胞系中 SWI/SNF 抑制的基因敏感性，从而提高 SWI/SNF 抑制剂的治疗潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37922899/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37922899</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.10.006>10.1016/j.cell.2023.10.006</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37922899</guid><pubDate> Fri, 03 Nov 2023 06:00:00 -0400</pubDate><dc:creator>本杰明·J·E·马丁</dc:creator><dc:creator>艾琳·F·阿布隆迪</dc:creator><dc:creator>克里斯汀·戈利亚</dc:creator><dc:creator>克劳迪娅·米莫索</dc:creator><dc:creator>皮耶罗·R·埃斯皮内尔·卡布雷拉</dc:creator><dc:creator>凯伦·阿德尔曼</dc:creator><dc:date>2023-11-03</dc:date><dc:source>细胞</dc:source><dc:title>SWI/SNF 目标的全球识别揭示了 EP400 的补偿</dc:title><dc:identifier>下午:37922899</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.006</dc:identifier></item><item><title>电路特异性基因疗法逆转灵长类帕金森病模型的核心症状</title><link/>https://pubmed.ncbi.nlm.nih.gov/37922901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>帕金森病 (PD) 是一种使人衰弱的神经退行性疾病。其症状通常采用左旋多巴或多巴胺受体激动剂治疗，但由于多巴胺受体广泛分布于中枢神经系统和外周，其作用缺乏特异性。在此，我们报告进展情况选择性操纵受 PD 影响的电路的基因治疗策略。针对纹状体 D1 中型多棘神经元 (MSN)，其活性在 PD 中长期受到抑制，我们设计了... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 30 日：S0092-8674(23)01086-3. doi: 10.1016/j.cell.2023.10.004. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">帕金森病 (PD) 是一种使人衰弱的神经退行性疾病。其症状通常采用左旋多巴或多巴胺受体激动剂治疗，但由于多巴胺受体广泛分布于中枢神经系统和外周，其作用缺乏特异性。在此，我们报告进展情况选择性操纵PD影响电路的基因治疗策略。针对纹状体D1中型多棘神经元（MSN），其活性在PD中长期受到抑制，我们设计了一种由高效逆行腺相关病毒（AAV）组成的治疗策略，具有强 D1-MSN 活性的启动子元件和化学遗传学效应子，可在全身配体给药后实现精确的 D1-MSN 激活。这种治疗方法的应用可挽救 PD 小鼠和灵长类动物模型中的运动、震颤和运动技能缺陷，支持用于治疗人类 PD 的靶向电路调制工具的可行性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37922901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37922901</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.10.004>10.1016/j.cell.2023.10.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37922901</guid><pubDate> Fri, 03 Nov 2023 06:00:00 -0400</pubDate><dc:creator>陈叶飞</dc:creator><dc:creator>洪泽轩</dc:creator><dc:creator>王静怡</dc:creator><dc:creator>刘坤林</dc:creator><dc:creator>刘静</dc:creator><dc:creator>林建邦</dc:creator><dc:creator>冯石景</dc:creator><dc:creator>张天慧</dc:creator><dc:creator>梁山</dc:creator><dc:creator>刘泰安</dc:creator><dc:creator>郭品跃</dc:creator><dc:creator>林云平</dc:creator><dc:creator>田丽</dc:creator><dc:creator>陈谦</dc:creator><dc:creator>蒋晓丹</dc:creator><dc:creator>李阿南</dc:creator><dc:creator>李翔</dc:creator><dc:creator>李元涛</dc:creator><dc:creator>乔纳森·王尔德</dc:creator><dc:creator>金宝</dc:creator><dc:creator>吉代</dc:creator><dc:creator>中华路中华路</dc:creator><dc:date>2023-11-03</dc:date><dc:source>细胞</dc:source><dc:title>电路特异性基因疗法逆转灵长类帕金森病模型的核心症状</dc:title><dc:identifier>下午:37922901</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.004</dc:identifier></item><item><title>哺乳动物卵母细胞在细胞质格子上储存早期胚胎的蛋白质</title><link/>https://pubmed.ncbi.nlm.nih.gov/37922900/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>哺乳动物卵母细胞充满了人们知之甚少的结构，称为细胞质格子。首次发现于 20 世纪 60 年代，推测对应于哺乳动物卵黄、核糖体阵列或中间丝，但迄今为止，它们的功能仍然是个谜。在这里，我们证明细胞质格子是卵母细胞储存早期胚胎发育必需的蛋白质。使用超分辨率光学显微镜和冷冻电子断层扫描，我们表明细胞质晶格是由...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 30 日：S0092-8674(23)01085-1. doi: 10.1016/j.cell.2023.10.003. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">哺乳动物卵母细胞充满了人们知之甚少的结构，称为细胞质格子。首次发现于 20 世纪 60 年代，推测对应于哺乳动物卵黄、核糖体阵列或中间丝，但迄今为止，它们的功能仍然是个谜。在这里，我们证明细胞质格子是卵母细胞储存早期胚胎发育必需的蛋白质。使用超分辨率光学显微镜和冷冻电子断层扫描，我们发现细胞质晶格由具有高表面积的细丝组成，其中含有 PADI6 和皮质下母体复合蛋白。这些晶格与许多关键蛋白质相关联用于胚胎发育，包括控制着床前胚胎表观遗传重编程的蛋白质。通过敲除 PADI6 或皮质下母体复合物而导致细胞质晶格的损失，可以防止这些蛋白质的积累并导致早期胚胎停滞。我们的工作表明，细胞质晶格丰富了母体提供的蛋白质蛋白质以防止其过早降解和细胞活性，从而促进哺乳动物的早期发育。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37922900/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37922900</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.10.003>10.1016/j.cell.2023.10.003</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37922900</guid><pubDate> Fri, 03 Nov 2023 06:00:00 -0400</pubDate><dc:creator>艾达·马·詹托夫特</dc:creator><dc:creator>菲利克斯·JB·鲍尔莱因</dc:creator><dc:creator>路易莎·韦尔普</dc:creator><dc:creator>本杰明·H·库珀</dc:creator><dc:creator>阿尔森·彼得罗维奇</dc:creator><dc:creator>春素</dc:creator><dc:creator>莎拉·梅·佩尼尔</dc:creator><dc:creator>安东尼奥·Z·波利蒂</dc:creator><dc:creator>叶霍尔·霍罗霍夫斯基</dc:creator><dc:creator>伊娜·塔卡拉</dc:creator><dc:creator>海克·埃克尔</dc:creator><dc:creator>吕迪格·莫特雷赫特</dc:creator><dc:creator>彼得·莱纳特</dc:creator><dc:creator>托马索·卡瓦扎</dc:creator><dc:creator>朱莉安·利佩</dc:creator><dc:creator>尼尔斯·布罗斯</dc:creator><dc:creator>亨宁·乌尔劳布</dc:creator><dc:creator>鲁本·费尔南德斯-布斯纳迭戈</dc:creator><dc:creator>梅琳娜·舒</dc:creator><dc:date>2023-11-03</dc:date><dc:source>细胞</dc:source><dc:title>哺乳动物卵母细胞在细胞质格子上储存早期胚胎的蛋白质</dc:title><dc:identifier>下午:37922900</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.003</dc:identifier></item><item><title>预防心房颤动：行动呼吁</title><link/>https://pubmed.ncbi.nlm.nih.gov/37919240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231106111053&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 31 日：ehad738。doi：10.1093/eurheartj/ehad738。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37919240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37919240</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad738>10.1093/eurheartj/ehad738</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37919240</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator>阿德里安·D·埃利奥特</dc:creator><dc:creator>埃米莉亚·J·本杰明</dc:creator><dc:creator>梅丽莎·E·米德尔多普</dc:creator><dc:date>2023-11-02</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>预防心房颤动：行动呼吁</dc:title><dc:identifier>下午：37919240</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad738</dc:identifier></item><item><title> The proteomic landscape of synaptic diversity across brain regions and cell types</title><link/> https://pubmed.ncbi.nlm.nih.gov/37918396/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231106111053&amp;v=2.17.9.post6+86293ac<description> Neurons build synaptic contacts using different protein combinations that define the specificity, function, and plasticity potential of synapses; however, the diversity of synaptic proteomes remains largely unexplored. We prepared synaptosomes from 7 different transgenic mouse lines with fluorescently labeled presynaptic terminals. Combining microdissection of 5 different brain regions with fluorescent-activated synaptosome sorting (FASS), we isolated and analyzed the proteomes of 18 different... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Oct 26:S0092-8674(23)01082-6. doi: 10.1016/j.cell.2023.09.028. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Neurons build synaptic contacts using different protein combinations that define the specificity, function, and plasticity potential of synapses; however, the diversity of synaptic proteomes remains largely unexplored. We prepared synaptosomes from 7 different transgenic mouse lines with fluorescently labeled presynaptic terminals. Combining microdissection of 5 different brain regions with fluorescent-activated synaptosome sorting (FASS), we isolated and analyzed the proteomes of 18 different synapse types. We discovered ∼1,800 unique synapse-type-enriched proteins and allocated thousands of proteins to different types of synapses (https://syndive.org/). We identify shared synaptic protein modules and highlight the proteomic hotspots for synapse specialization. We reveal unique and common features of the striatal dopaminergic proteome and discover the proteome signatures that relate to the functional properties of different interneuron classes. This study provides a molecular systems-biology analysis of synapses and a framework to integrate proteomic information for synapse subtypes of interest with cellular or circuit-level experiments.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37918396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37918396</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.09.028>10.1016/j.cell.2023.09.028</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37918396</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Marc van Oostrum</dc:creator><dc:creator> Thomas M Blok</dc:creator><dc:creator> Stefano L Giandomenico</dc:creator><dc:creator> Susanne Tom Dieck</dc:creator><dc:creator> Georgi Tushev</dc:creator><dc:creator> Nicole Fürst</dc:creator><dc:creator> Julian D Langer</dc:creator><dc:creator> Erin M Schuman</dc:creator><dc:date> 2023-11-02</dc:date><dc:source> Cell</dc:source><dc:title> The proteomic landscape of synaptic diversity across brain regions and cell types</dc:title><dc:identifier> pmid:37918396</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.028</dc:identifier></item><item><title> Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa</title><link/> https://pubmed.ncbi.nlm.nih.gov/37918395/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231106111053&amp;v=2.17.9.post6+86293ac<description> Drug-resistant Pseudomonas aeruginosa (PA) poses an emerging threat to human health with urgent need for alternative therapeutic approaches. Here, we deciphered the B cell and antibody response to the virulence-associated type III secretion system (T3SS) in a cohort of patients chronically infected with PA. Single-cell analytics revealed a diverse B cell receptor repertoire directed against the T3SS needle-tip protein PcrV, enabling the production of monoclonal antibodies (mAbs) abrogating... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Oct 27:S0092-8674(23)01084-X. doi: 10.1016/j.cell.2023.10.002. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Drug-resistant Pseudomonas aeruginosa (PA) poses an emerging threat to human health with urgent need for alternative therapeutic approaches. Here, we deciphered the B cell and antibody response to the virulence-associated type III secretion system (T3SS) in a cohort of patients chronically infected with PA. Single-cell analytics revealed a diverse B cell receptor repertoire directed against the T3SS needle-tip protein PcrV, enabling the production of monoclonal antibodies (mAbs) abrogating T3SS-mediated cytotoxicity. Mechanistic studies involving cryoelectron microscopy identified a surface-exposed C-terminal PcrV epitope as the target of highly neutralizing mAbs with broad activity against drug-resistant PA isolates. These anti-PcrV mAbs were as effective as treatment with conventional antibiotics in vivo. Our study reveals that chronically infected patients represent a source of neutralizing antibodies, which can be exploited as therapeutics against PA.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37918395/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37918395</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.10.002>10.1016/j.cell.2023.10.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37918395</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Alexander Simonis</dc:creator><dc:creator> Christoph Kreer</dc:creator><dc:creator> Alexandra Albus</dc:creator><dc:creator> Katharina Rox</dc:creator><dc:creator> Biao Yuan</dc:creator><dc:creator> Dmitriy Holzmann</dc:creator><dc:creator> Joana A Wilms</dc:creator><dc:creator> Sylvia Zuber</dc:creator><dc:creator> Lisa Kottege</dc:creator><dc:creator> Sandra Winter</dc:creator><dc:creator> Meike Meyer</dc:creator><dc:creator> Kristin Schmitt</dc:creator><dc:creator> Henning Gruell</dc:creator><dc:creator> Sebastian J Theobald</dc:creator><dc:creator> Anna-Maria Hellmann</dc:creator><dc:creator> Christina Meyer</dc:creator><dc:creator> Meryem Seda Ercanoglu</dc:creator><dc:creator> Nina Cramer</dc:creator><dc:creator> Antje Munder</dc:creator><dc:creator> Michael Hallek</dc:creator><dc:creator> Gerd Fätkenheuer</dc:creator><dc:creator> Manuel Koch</dc:creator><dc:creator> Harald Seifert</dc:creator><dc:creator> Ernst Rietschel</dc:creator><dc:creator> Thomas C Marlovits</dc:creator><dc:creator> Silke van Koningsbruggen-Rietschel</dc:creator><dc:creator> Florian Klein</dc:creator><dc:creator> Jan Rybniker</dc:creator><dc:date> 2023-11-02</dc:date><dc:source> Cell</dc:source><dc:title> Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa</dc:title><dc:identifier> pmid:37918395</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.002</dc:identifier></item><item><title> Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells</title><link/> https://pubmed.ncbi.nlm.nih.gov/37918394/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231106111053&amp;v=2.17.9.post6+86293ac<description> Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most common autoimmune encephalitis, leading to psychosis, seizures, and autonomic dysfunction. Current treatments comprise broad immunosuppression or non-selective antibody removal. We developed NMDAR-specific chimeric autoantibody receptor (NMDAR-CAAR) T cells to selectively eliminate anti-NMDAR B cells and disease-causing autoantibodies. NMDAR-CAARs consist of an extracellular multi-subunit NMDAR autoantigen fused to... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Oct 26:S0092-8674(23)01083-8. doi: 10.1016/j.cell.2023.10.001. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most common autoimmune encephalitis, leading to psychosis, seizures, and autonomic dysfunction. Current treatments comprise broad immunosuppression or non-selective antibody removal. We developed NMDAR-specific chimeric autoantibody receptor (NMDAR-CAAR) T cells to selectively eliminate anti-NMDAR B cells and disease-causing autoantibodies. NMDAR-CAARs consist of an extracellular multi-subunit NMDAR autoantigen fused to intracellular 4-1BB/CD3ζ domains. NMDAR-CAAR T cells recognize a large panel of human patient-derived autoantibodies, release effector molecules, proliferate, and selectively kill antigen-specific target cell lines even in the presence of high autoantibody concentrations. In a passive transfer mouse model, NMDAR-CAAR T cells led to depletion of an anti-NMDAR B cell line and sustained reduction of autoantibody levels without notable off-target toxicity. Treatment of patients may reduce side effects, prevent relapses, and improve long-term prognosis. Our preclinical work paves the way for CAAR T cell phase I/II trials in NMDAR encephalitis and further autoantibody-mediated diseases.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37918394/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37918394</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.10.001>10.1016/j.cell.2023.10.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37918394</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator> S Momsen Reincke</dc:creator><dc:creator> Niels von Wardenburg</dc:creator><dc:creator> Marie A Homeyer</dc:creator><dc:creator> Hans-Christian Kornau</dc:creator><dc:creator> Gregorio Spagni</dc:creator><dc:creator> Lucie Y Li</dc:creator><dc:creator> Jakob Kreye</dc:creator><dc:creator> Elisa Sánchez-Sendín</dc:creator><dc:creator> Sonja Blumenau</dc:creator><dc:creator> Dominik Stappert</dc:creator><dc:creator> Helena Radbruch</dc:creator><dc:creator> Anja E Hauser</dc:creator><dc:creator> Annette Künkele</dc:creator><dc:creator> Inan Edes</dc:creator><dc:creator> Dietmar Schmitz</dc:creator><dc:creator> Harald Prüss</dc:creator><dc:date> 2023-11-02</dc:date><dc:source> Cell</dc:source><dc:title> Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells</dc:title><dc:identifier> pmid:37918394</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.001</dc:identifier></item><item><title> 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/37914787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231106111053&amp;v=2.17.9.post6+86293ac<description> Rheumatic heart disease (RHD) is an important and preventable cause of morbidity and mortality among children and young adults in low-income and middle-income countries, as well as among certain at-risk populations living in high-income countries. The 2012 World Heart Federation echocardiographic criteria provided a standardized approach for the identification of RHD and facilitated an improvement in early case detection. The 2012 criteria were used to define disease burden in numerous... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol. 2023 Nov 2. doi: 10.1038/s41569-023-00940-9. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Rheumatic heart disease (RHD) is an important and preventable cause of morbidity and mortality among children and young adults in low-income and middle-income countries, as well as among certain at-risk populations living in high-income countries. The 2012 World Heart Federation echocardiographic criteria provided a standardized approach for the identification of RHD and facilitated an improvement in early case detection. The 2012 criteria were used to define disease burden in numerous epidemiological studies, but researchers and clinicians have since highlighted limitations that have prompted a revision. In this updated version of the guidelines, we incorporate evidence from a scoping review, an expert panel and end-user feedback and present an approach for active case finding for RHD, including the use of screening and confirmatory criteria. These guidelines also introduce a new stage-based classification for RHD to identify the risk of disease progression. They describe the latest evidence and recommendations on population-based echocardiographic active case finding and risk stratification. Secondary antibiotic prophylaxis, echocardiography equipment and task sharing for RHD active case finding are also discussed. These World Heart Federation 2023 guidelines provide a concise and updated resource for clinical and research applications in RHD-endemic regions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37914787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37914787</a> | DOI: <a href=https://doi.org/10.1038/s41569-023-00940-9>10.1038/s41569-023-00940-9</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37914787</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Joselyn Rwebembera</dc:creator><dc:creator> James Marangou</dc:creator><dc:creator> Julius Chacha Mwita</dc:creator><dc:creator> Ana Olga Mocumbi</dc:creator><dc:creator> Cleonice Mota</dc:creator><dc:creator> Emmy Okello</dc:creator><dc:creator> Bruno Nascimento</dc:creator><dc:creator> Lene Thorup</dc:creator><dc:creator> Andrea Beaton</dc:creator><dc:creator> Joseph Kado</dc:creator><dc:creator> Alexander Kaethner</dc:creator><dc:creator> Raman Krishna Kumar</dc:creator><dc:creator> John Lawrenson</dc:creator><dc:creator> Eloi Marijon</dc:creator><dc:creator> Mariana Mirabel</dc:creator><dc:creator> Maria Carmo Pereira Nunes</dc:creator><dc:creator> Daniel Piñeiro</dc:creator><dc:creator> Fausto Pinto</dc:creator><dc:creator> Kate Ralston</dc:creator><dc:creator> Craig Sable</dc:creator><dc:creator> Amy Sanyahumbi</dc:creator><dc:creator> Anita Saxena</dc:creator><dc:creator> Karen Sliwa</dc:creator><dc:creator> Andrew Steer</dc:creator><dc:creator> Satupaitea Viali</dc:creator><dc:creator> Gavin Wheaton</dc:creator><dc:creator> Nigel Wilson</dc:creator><dc:creator> Liesl Zühlke</dc:creator><dc:creator> Bo Reményi</dc:creator><dc:date> 2023-11-02</dc:date><dc:source> Nature reviews. Cardiology</dc:source><dc:title> 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease</dc:title><dc:identifier> pmid:37914787</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00940-9</dc:identifier></item><item><title> Reply: Targeting Symptom Preoccupation in Atrial Fibrillation: A Promising Treatment Approach and Avenue for Future Research</title><link/> https://pubmed.ncbi.nlm.nih.gov/37914521/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231106111053&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Nov 7;82(19):e183-e184. doi: 10.1016/j.jacc.2023.08.047.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37914521/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37914521</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.047>10.1016/j.jacc.2023.08.047</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37914521</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Josefin Särnholm</dc:creator><dc:creator> Brjánn Ljótsson</dc:creator><dc:creator> Frieder Braunschweig</dc:creator><dc:date> 2023-11-01</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Reply: Targeting Symptom Preoccupation in Atrial Fibrillation: A Promising Treatment Approach and Avenue for Future Research</dc:title><dc:identifier> pmid:37914521</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.047</dc:identifier></item><item><title> Caution Warranted Regarding the Efficacy of iCBT in Patients With Symptomatic Paroxysmal Atrial Fibrillation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37914520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231106111053&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Nov 7;82(19):e181. doi: 10.1016/j.jacc.2023.07.035.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37914520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37914520</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.035>10.1016/j.jacc.2023.07.035</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37914520</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Peter Andersson</dc:creator><dc:creator> James Coyne</dc:creator><dc:date> 2023-11-01</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Caution Warranted Regarding the Efficacy of iCBT in Patients With Symptomatic Paroxysmal Atrial Fibrillation</dc:title><dc:identifier> pmid:37914520</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.035</dc:identifier></item><item><title> Postmenopausal Women With Atrial Fibrillation and Mental Health Symptoms: A Group Deserving Attention</title><link/> https://pubmed.ncbi.nlm.nih.gov/37914519/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231106111053&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Nov 7;82(19):e179. doi: 10.1016/j.jacc.2023.07.037.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37914519/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37914519</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.037>10.1016/j.jacc.2023.07.037</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37914519</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Jieyi Wang</dc:creator><dc:creator> Ruiting Jia</dc:creator><dc:creator> Yulin Lu</dc:creator><dc:creator> Wumin Yu</dc:creator><dc:creator> Aisong Zhu</dc:creator><dc:date> 2023-11-01</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Postmenopausal Women With Atrial Fibrillation and Mental Health Symptoms: A Group Deserving Attention</dc:title><dc:identifier> pmid:37914519</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.037</dc:identifier></item><item><title> Beyond the Surface: Scrutinizing Methodological Biases in a Study on iCBT for Atrial Fibrillation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37914518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231106111053&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Nov 7;82(19):e177. doi: 10.1016/j.jacc.2023.07.036.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37914518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231106111053&v=2.17.9.post6+86293ac">37914518</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.036>10.1016/j.jacc.2023.07.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37914518</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Adrian E Desai Boström</dc:creator><dc:creator> Johan Lundberg</dc:creator><dc:date> 2023-11-01</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Beyond the Surface: Scrutinizing Methodological Biases in a Study on iCBT for Atrial Fibrillation</dc:title><dc:identifier> pmid:37914518</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.036</dc:identifier></item></channel></rss>